Compare Crispr Therapeutics AG (CRSP) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Norwegian Cruise Line Holdings Ltd — how do they compare? Crispr Therapeutics AG trades at $50.36 (market cap $4.97B), while Norwegian Cruise Line Holdings Ltd trades at $20.02 (market cap $8.93B). The key difference: Norwegian Cruise Line Holdings Ltd is the larger of the two by market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | NCLH | |
|---|---|---|
Market Cap | $4.97B | $8.93B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $26.94 |
52-Week Low | $44.34 | $14.79 |
Enterprise Value | $3.32B | $23.90B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
Norwegian Cruise Line Holdings (NCLH) trades at $19.63, up 0.1% on the day, with a neutral technical signal and strong analyst consensus. Recent earnings beats and a 55.55% buy rating from analysts support optimism, though the stock faces headwinds from high debt levels and volatile cash flows. Revenue growth has improved from $4.8B in 2022 to $9.83B in 2025, but net margins remain modest at 4.3%.
The outlook is cautiously positive, with a consensus price target of $21.71 offering ~11% upside. Key opportunities include falling energy costs and robust booking trends, while risks involve elevated leverage and macroeconomic sensitivity. Investors should weigh solid fundamentals against balance sheet constraints.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
